Læknablaðið - 15.09.2007, Blaðsíða 29

FRÆÐIGREIN / LUNGNABÓLGA
22 Mathew BS, Grossman SA. Pneumocystis carinii pneumonia
prophylaxis in HIV negative patients with primary CNS
lymphoma.CancerTreat Rev. 2003 Apr;29(2):105-19
23 Warnock AC, Rimland D. Comparison of trimethoprim-
su!famethoxazole,dapsone,and pentamidine in the prophylaxis
of Pneumocystis carinii pneumonia. Pharmacotherapy. 1996
Nov-Dec;16(6):1030-8.
24 SlivkaA.Wen PY,Shea WM.Loeffler JS. Pneumocystis carinii
pneumonia during steroid taper in patients with primary brain
tumors. Am J Med. 1993 Feb;94(2):216-9.
25 Walzer PD, Powell RD Jr, Yoneda K, Rutledge ME, Milder
JE. Growth characteristics and pathogenesis of experimental
Pneumocystis carinii pneumonia. Infect Immun. 1980
Mar;27(3):928-37.
26 Walzer PD, LaBine M, Redington TJ, Cushion MT.
Lymphocyte changes during chronic administration of and
withdrawal from corticosteroids: relation to Pneumocystis
carinii pneumonia. J Immunol. 1984 Nov;133(5):2502-8.
27 Mansharamani NG, Balachandran D, Vernovsky I, Garland R.
Koziel H. Peripheral blood CD4 +T-lymphocyte counts during
Pneumocystis carinii pneumonia in immunocompromised
patients without HIV infection. Chest. 2000 Sep;118(3):712-
20.
28 Briel M, Bucher HC, Boscacci R, Furrer H. Adjunctive
corticosteroids for Pneumocystis jiroveci pneumonia in
patients with HlV-infection. Cochrane Database Syst Rev.
2006 Jul 19;3:CD006150.
29 Pareja JG, Garland R, Koziel H.Use of adjunctive
corticosteroids in severe adult non-HIV Pneumocystis carinii
pneumonia. Chest. 1998 May;113(5):1215-24.
30 Delclaux C, Zahar JR, Amraoui G, Leleu G, Lebargy F,
Brochard L, et al. Corticosteroids as adjunctive therapy
for severe Pneumocystis carinii pneumonia in non-human
immunodeficiency virus-infected patients: retrospective study
of 31 patients. Clin Infect Dis. 1999 Sep;29(3):670-2.
31 Kremer JM. Methotrexate and leflunomide: biochemical
basis for combination therapy in the treatment of rheumatoid
arthritis. Semin Arthritis Rheum. 1999 Aug;29(l):14-26.
32 Sérlyfjaskrá Lyfjastofnunar íslands. Vefsíöa: http://www.
lyfjastofnun.is /júlí 2007
33 Goldie JH, Price LA, Harrap KR. Methotrexate toxicity:
correlation with duration of administration, plasma levels,
dose and excretion pattem. Eur J Cancer 1972; 8:409-14.
34 Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P,
Revillard JP. Immunosuppressive properties of methotrexate:
apoptosis and clonal deletion of activated peripheral T cells. J
Clin Invest 1998 15; 102:322-8.
35 Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson
BR, Valdimarsson H. The anti-inflammatory action of
methotrexate is not mediated by lymphocyte apoptosis, but
by the suppression of activation and adhesion molecules. Clin
Immunol 2005; 114:154-63.
36 Weinblatt ME, Maier AL, Fraser PA, Coblyn JS. Longterm
prospective study of methotrexate in rheumatoid arthritis:
conclusion after 132 months of therapy. J Rheumatol. 1998; 25:
238-42.
37 Krebs S, Gibbons RB. Low-dose methotrexate as a risk
factor for Pneumocystis carinii pneumonia. Mil Med. 1996
Jan;161(l):58-60.
38 Kaneko Y, Suwa A, Ikeda Y, Hirakata M. Pneumocystis
jiroveci pneumonia associated with low-dose methotrexate
treatment for rheumatoid arthritis: report of two cases and
review of the literature. Mod Rheumatol. 2006;16(l):36-8.
39 Marinosa M, Soler A, Nogues X, Pedro-Botet J. Pulmonary
coinfection by Pneumocystis carinii and Aspegillus fumigatus
in a seronegative arthritis patient treated with low-dose
methotrexate. Clin Rheumatol. 2004 Dec;23(6):555-6.
40 Roblot F, Godet C, Le Moal G, Garo B, Faouzi Souala M,
Dary M, et al. Analysis of underlying diseases and prognosis
factors associated with Pneumocystis carinii pneumonia in
immunocompromised HlV-negative patients. Eur J Clin
Microbiol Infect Dis. 2002 Jul;21(7):523-31
41 Barbier C, Arnaout L, Schmit C, Aucouturier JS, Ricome JL,
Loubieres Y. Respiratory failure due to Pneumocystis carinii
following methotrexate therapy for gestational trophoblastic
disease. BJOG. 2005 Mar;112(3):382-3
42 Frenia ML, Long KS. Methotrexate and nonsteroidal
antiinflammatory drug interactions. Ann Pharmacother. 1992
Feb;26(2):234-7
43 Hilliquin P, Renoux M, Perrot S, Puechal X, Menkes CJ.
Occurrence of pulmonary complications during methotrexate
therapy in rheumatoid arthritis. Br J Rheumatol. 1996
May;35(5):441-5.
44 Duncan KO, Imaeda S, Milstone LM. Pneumocystis carinii
pneumonia complicating methotrexate treatment of pityriasis
rubra pilaris. J Am Acad Dermatol. 1998 Aug;39(2 Pt l):276-8.
45 Helm RM,Wheeler G, Burks AW,Hakkak R,BadgerTM.Flow
cytometric analysis of lymphocytes from rats following chronic
ethanol treatment. Alcohol. 1996 Sep-Oct;13(5):467-71.
46 Jerrells TR, Marietta CA, Bone G, Weight FF, Eckardt
MJ. Ethanol-associated immunosuppression. Adv Biochem
Psychopharmacol. 1988;44:173-85.
47 Jerrells TR, Marietta CA, Eckardt MJ, Majchrowicz E, Weight
FF. Effects of ethanol administration on parameters of
immunocompetency in rats. J Leukoc Biol. 1986 May;39(5):499-
510.
48 Ali MV, Nolan JP. Alcohol induced depression of
reticuloendothelial function in the rat. J Lab Clin Med. 1967
Aug;70(2):295-301.
49 Szabo G. Consequences of alcohol consumption on host
defence. Alcohol Alcohol. 1999 Nov-Dec;34(6):830-41.
50 Pauly T, Dahmen N, Szegedi A, Wetzel H, Bol GF, Ferdinand
K et al. Blood ethanol levels and adenylyl cyclase activity in
lymphocytes of alcoholic patients. Biol Psychiatry. 1999 Feb
15;45(4):489-93.
51 Roselle GA, Mendenhall CL, Grossman CJ, Weesner RE.
Lymphocyte subset alterations in patients with alcoholic
hepatitis. J Clin Lab Immunol. 1988 Aug;26(4):169-73.
52 Roselle GA, Mendenhall CL, Chedid A, Moritz TE, Gartside
P. Alcohol modulation of immune function: clinical and
experimental data. Alcohol Clin Exp Res. 1995 Jun;19(3):551-
4.
53 Chiappelli F, Kung M, Lee P, Pham L, Manfrini E, Villanueva
P. Alcohol modulation of human normal T-cell activation,
maturation, and migration. Alcohol Clin Exp Res. 1995
Jun;19(3):539-44.
54 Ichai P, Azoulay D, Feray C, Saliba F, Antoun F, Roche B, et
al. Pneumocystis carinii and cytomegalovirus pneumonia after
corticosteroid therapy in acute severe alcoholic hepatitis: 2
case reports. Gastroenterol Clin Biol. 2002 May;26(5):532-4.
55 Riebold D, Hennig A, Loebermann M, Schareck W, Reisinger
EC. Pneumocystis pneumonia in an alcoholic patient with
prolonged mechanical ventilation. Eur J Clin Microbiol Infect
Dis. 2005 Apr;24(4):294-6.
56 Latif O, Peterson JD, Waltenbaugh C. Alcohol-mediated
polarization of type 1 and type 2 immune responses. Front
Biosci. 2002 Aug 1 ;7:al35-47.
57 D‘Souza NB. Nelson S, Summer WR, Deaciuc IV. Alcohol
modulates alveolar macrophage tumor necrosis factor-alpha,
superoxide anion, and nitric oxide secretion in the rat. Alcohol
Clin Exp Res. 1996 Feb;20(l):156-63.
58 Bagasra O, Howeedy A, Kajdacsy-Balla A. Macrophage
function in chronic experimental alcoholism. I. Modulation
of surface receptors and phagocytosis. Immunology. 1988
Nov;65(3):405-9.
59 Mandrekar P, Dolganiuc A, Bellerose G, Kodys K, Romics
L, Nizamani R, et al. Acute alcohol inhibits the induction of
nuclear regulatory factor kappa B activation through CD14/
toll-like receptor 4, interleukin-1, and tumor necrosis factor
receptors: a common mechanism independent of inhibitory
kappa B alpha degradation? Alcohol Clin Exp Res. 2002
Nov;26( 11): 1609-14.
60 MacGregor RR, Gluckman SJ, Senior JR. Granulocyte
function and levels of immunoglobulins and complement in
patients admitted for withdrawal from alcohol. J Infect Dis.
1978 Dec;138(6):747-55.
61 Zhang P, Bagby GJ, Xie M, Stoltz DA, Summer WR, Nelson S.
Acute ethanol intoxication inhibits neutrophil beta2-integrin
expression in rats during endotoxemia. Alcohol Clin Exp Res.
1998 Feb;22(l): 135-41.
62 Tamura DY. Moore EE, Partrick DA, Johnson JL, Offner PJ,
Harbeck RJ,et al. Clinically relevant concentrations of ethanol
attenuate primed neutrophil bactericidal activity. J Trauma.
1998 Feb;44(2):320-4.
63 Iikuni N, Kitahama M, Ohta S, Okamoto H, Kamatani N,
Nishinarita M. Evaluation of Pneumocystis pneumonia
infection risk factors in patients with connective tissue disease.
Mod Rheumatol. 2006;16(5):282-8.
Læknablaðið 2007/93 613